-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
FC131-TFA
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/fc131-tfa.gif)
| Category | Human immunodeficiency Virus (HIV) |
| Description | FC131 TFA is a CXCR4 antagonist, inhibits [125I]-SDF-1 binding to CXCR4, with an IC50 of 4.5 nM. |
Product Information
| Synonyms | FC131 TFA |
| Molecular Weight | 843.85 |
| Molecular Formula | C38H48F3N11O8 |
| Purity | 98.38% |
| Density | 1.5±0.1 g/cm3 |
| Solubility | In Vitro: DMSO : 250 mg/mL(296.26 mM;Need ultrasonic) In Vivo: 1.Add each solvent one by one:10% DMSO >> 40%PEG300 >> 5%Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (2.46 mM); Clear solution 2.Add each solvent one by one:10% DMSO >> 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.08 mg/mL (2.46 mM); Clear solution 3.Add each solvent one by one:10% DMSO >> 90%corn oil Solubility: ≥ 2.08 mg/mL (2.46 mM); Clear solution |
| Appearance | White to off-white (Solid) |
| Storage | Sealed storage, away from moisture and light Powder -80°C 2 years -20°C 1 years * In solvent -80°C 6 months -20°C 1 month (sealed storage, away from moisture and light) |
| Index Of Refraction | 1.696 |
| PSA | 289.53000 |
| Target | CXCR; HIV |
